ENDPOINTS

Novartis’ radiopharma drug Pluvicto gets an expanded label

Novartis’ prostate cancer radiopharmaceutical Pluvicto has netted a highly anticipated and highly delayed expanded indication. The FDA on Friday approved the drug for certain patients before they have received chemotherapy, making ...

Mar 29, 2025 - 00:20
 0
Novartis’ radiopharma drug Pluvicto gets an expanded label
Novartis’ prostate cancer radiopharmaceutical Pluvicto has netted a highly anticipated and highly delayed expanded indication. The FDA on Friday approved the drug for certain patients before they have received chemotherapy, making ...
Read More

Tags:

Previous Article

Measles is spreading across the US – here is what you need to know

Next Article

NASA's New Dust Repelling Shield Seems to Work Well

Related Posts

Acelyrin and Alumis to merge in deal combining cash, assets

Acelyrin and Alumis to merge in deal combining cash, as...

Feb 9, 2025  0

Pfizer’s manufacturing arm at risk from Trump tariffs in Europe, Bourla says

Pfizer’s manufacturing arm at risk from Trump tariffs i...

Feb 19, 2025  0

RFK Jr. convened roundtable around ways to reduce stem cell regulation

RFK Jr. convened roundtable around ways to reduce stem ...

Mar 14, 2025  0